Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study

Inclusion Criteria: * Participated in Protocol FB401-01, completed through Week 20 visit and able to directly enroll into this (FB401-02) study * Refrain from use of all other atopic dermatitis treatments, unless given permission by medical monitor Exclusion Criteria: * Subject experienced a serious adverse event or severe adverse event attributable to study drug in Protocol FB401-01 * Severe concomitant illness that, in the Investigator's opinion, would adversely affect subject participation in the study, whether medical or psychological * Pregnant (or planning to become pregnant during the period of the study) or lactating females